Targeting MicroRNAs to limit myocardial lipid accumulation

Circulation Research

Volumn 116, Issue 2, 2015, Pages 229-231

  Lopaschuk, Gary D ^a   Ussher, John R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

AMP activated protein kinases; cardiomyopathies; ceramides; Editorials; heart; microRNA; obesity

Indexed keywords

ADENYLATE KINASE; CERAMIDE; MICRORNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MIRN451 MICRORNA, MOUSE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, MOUSE;

CARDIOMYOPATHY; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE TARGETING; HEART MUSCLE; HEART PROTECTION; LIPID STORAGE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; CARDIOMEGALY; HEART MUSCLE CELL; LIPID DIET; MALE; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; DIET, HIGH-FAT; MALE; MICRORNAS; MYOCYTES, CARDIAC; PROTEIN-SERINE-THREONINE KINASES;

EID: 84921969105     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.305675     Document Type: Editorial

References (27)

1. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313. doi: 10.1056/NEJMoa020245.
2. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J. 2006;27:96-106. doi: 10.1093/eurheartj/ehi506.
3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
4. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV; Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861-867.
5. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335-347. doi: 10.1161/CIRCRESAHA 150417.
6. Ussher JR. The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Expert Rev Cardiovasc Ther. 2014;12:345-358. doi: 10.1586/14779072.2014.891939.
7. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation- A novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 2011;1813:1333-1350. doi: 10.1016/j.bbamcr.2011.01.015.
8. Ussher JR, Koves TR, Jaswal JS, Zhang L, Ilkayeva O, Dyck JR, Muoio DM, Lopaschuk GD. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes. 2009;58:1766-1775. doi: 10.2337/db09-0011.
9. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev. 2009;89:1025-1078. doi: 10.1152/physrev.00011.2008.
10. Ussher JR, Jaswal JS, Wagg CS, Armstrong HE, Lopaschuk DG, Keung W, Lopaschuk GD. Role of the atypical protein kinase Czeta in regulation of 5'-AMP-activated protein kinase in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297:E349-E357. doi: 10.1152/ajpendo.00009.2009.
11. Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S, Izuhara M, Nakao T, Nishino T, Otsu K, Kita T, Kimura T, Ono K. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and highfat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res. 2015;116:279-288. doi: 10.1161/CIRCRESAHA.116.304707.
12. Harada M, Luo X, Murohara T, Yang B, Dobrev D, Nattel S. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ Res. 2014;114:689-705. doi: 10.1161/CIRCRESAHA.114.301798.
13. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123:11-18. doi: 10.1172/JCI62876.
14. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E, Matsuzaki S, Humphries KM, Hill JA, Bassel-Duby R, Sadek HA, Olson EN. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca?+ overload and cell death. J Clin Invest. 2012;122:1222-1232. doi: 10.1172/JCI59327.
15. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535-548. doi: 10.1084/jem.20101812.
16. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, Hu X, Wang DZ. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res. 2014;114:1585-1595. doi: 10.1161/CIRCRESAHA.114.303784.
17. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol. 2006;574:95-112. doi: 10.1113/jphysiol.2006.109389.
18. Ussher JR, Folmes CD, Keung W, Fillmore N, Jaswal JS, Cadete VJ, Beker DL, Lam VH, Zhang L, Lopaschuk GD. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One. 2012;7:e37703. doi: 10.1371/journal.pone.0037703.
19. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res. 2011;89:148-156. doi: 10.1093/cvr/cvq266.
20. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696-705. doi: 10.2337/db07-1098.
21. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, Li H, Rathi S, Dong Y, Tian R, Kem D, Zou MH. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60:1770-1778. doi: 10.2337/db10-0351.
22. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, Walser M, Samà M, Aimaretti G, Isgaard J, Saccà L. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes. 2012;61:944-953. doi: 10.2337/db11-1132.
23. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513-17520.
24. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191-2196. doi: 10.1161/01.CIR.0000127959.28627.F8.
25. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008;49:2101-2112. doi: 10.1194/jlr.M800147-JLR200.
26. Sung MM, Koonen DP, Soltys CL, Jacobs RL, Febbraio M, Dyck JR. Increased CD36 expression in middle-aged mice contributes to obesityrelated cardiac hypertrophy in the absence of cardiac dysfunction. J Mol Med (Berl). 2011;89:459-469. doi: 10.1007/s00109-010-0720-4.
27. Baranowski M, Blachnio-Zabielska A, Hirnle T, Harasiuk D, Matlak K, Knapp M, Zabielski P, Gorski J. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res. 2010;51:74-80. doi: 10.1194/jlr.M900002-JLR200.